In　recent　years,　organic　chromium　(III)　supplements　have　received　increasing　attentions　for　their　low　toxicity,　high　bioavailability　and　wide　range　of　health-promoting　benefits.　This　study　aimed　to　investigate　the　preventive　effects　of　chromium　(III)-enriched　yeast　(YCr)　on　high-fat　and　high-fructose　diet　(HFHFD)-induced　hyperlipid-emia　and　hyperglycemia　in　mice,　and　further　clarify　its　mechanism　of　action　from　the　perspective　of　intestinal　microbiomics　and　liver　metabolomics.　The　results　indicated　that　oral　administration　of　YCr　remarkably　inhibited　the　aberrant　elevations　of　body　weight,　blood　glucose　and　lipid　levels,　hepatic　cholesterol　(TC)　and　triglyceride　(TG)　levels　caused　by　HFHFD.　Liver　histological　examination　showed　that　oral　YCr　intervention　inhibited　HFHFD　induced　liver　lipid　accumulation.　Besides,　16S　rDNA　amplicon　sequencing　showed　that　YCr　intervention　was　beneficial　to　ameliorating　intestinal　microbiota　dysbiosis　by　altering　the　proportion　of　some　intestinal　microbial　phylotypes.　Correlation-based　network　analysis　indicated　that　the　key　intestinal　microbial　phylotypes　intervened　by　YCr　were　closely　related　to　some　biochemical　parameters　associated　with　glucose　and　lipid　metabolism.　Liver　metabolomics　analysis　revealed　that　dietary　YCr　intervention　significantly　regulated　the　levels　of　some　bio-markers　involved　in　purine　metabolism,　glycerophospholipid　metabolism,　citrate　cycle,　pyrimidine　metabolism,　glycerophospholipid　metabolism,　phenylalanine,　tyrosine　and　tryptophan　biosynthesis,　and　so　on.　Moreover,　dietary　YCr　intervention　regulated　the　mRNA　levels　of　key　genes　associated　with　glucose,　cholesterol,　fatty　acids　and　bile　acids　metabolism　in　liver.　These　findings　suggest　that　dietary　YCr　intervention　has　beneficial　effects　on　glucose　and　lipid　metabolism　by　regulating　intestinal　microbiota　and　liver　metabolic　pathway,　and　thus　can　be　served　as　a　functional　component　to　prevent　hyperlipidemia　and　hyperglycemia.